Csaba Poroszlai started his professional career at Béres Pharmaceuticals Co. in 1998. Holding the position of Chief Financial Officer between 2003 and 2008, he gained outstanding professional and sectoral experience. Csaba Poroszlai joined Egis in 2008: as Head of Strategic Controlling, he was responsible for the development of high priority controlling systems. In 2011, he was appointed Chief Financial Officer and became a member of the Board of Directors of Egis.

The appointment of Csaba Poroszlai ends the interim period which started in February this year when, following the former CEO’s departure, he was asked to temporarily fill the position until the selection process for a new CEO is completed.

During his term as interim CEO, Csaba Poroszlai was supported by Balázs Vándor Chief Accountant and Deputy Chief Financial Officer. At the same time as this decision, Balázs Vándor was appointed Chief Financial Officer.

Balázs Vándor joined Egis in 1995. From 2003 he worked as deputy chief accountant, then, after a short assignment as chief internal audit officer from 2010 he held the positions of chief accountant, deputy accounting director and then accounting director.

Egis is one of the region’s significant generic pharmaceutical companies. Its products are available in sixty-one countries, appr. thirty million patients are treated with Egis medicines yearly. As one of Hungary’s leading generic manufacturers, Egis sells the most prescription medicines in pharmacies in Hungary. To treat cardiovascular disease, doctors most often choose Egis medications for their patients, while Egis products are the second most common therapeutic indication for central nervous system diseases in our country. *

^{*Source: MAT04 2022 IQVIA (May 2021 – April 2022)}